Print

New Phase 2 Data From Brain Cancer Study With Agenus (Formerly known as Antigenics Inc. - New York) (AGEN)' Prophage Vaccine (HSPPC-96) Presented at Plenary Session of AANS  
4/17/2012 9:41:30 AM

LEXINGTON, Mass., April 17, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) today announced that an abstract entitled, "A Phase 2 multicenter trial of autologous heat shock protein-peptide vaccine (HSPPC-96; vitespen) for recurrent glioblastoma multiforme (GBM) patients shows improved survival compared to a contemporary cohort controlled for age, KPS and extent of resection," was presented by Dr. Andrew Parsa, Professor, Department of Neurological Surgery, University of California San Francisco, during Plenary Session II at the 80th American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in Miami, Florida.
//-->